Comparison of Functional Outcome Between Intra-Articular Injection of Corticosteroid Versus Platelet-Rich Plasma in Frozen Shoulder: A Randomized Controlled Trial

Hafiz Faisal Shahzad 1, Muhammad Taqi 2, Syed Faraz Ul Hassan Shah Gillani 3, Faisal Masood 3, Munawar Ali 4

1. Orthopedic Unit-1, Mayo Hospital, Lahore, PAK 2. Orthopedics and Traumatology, Mayo Hospital, Lahore, PAK 3. Orthopedic Surgery, Mayo Hospital, Lahore, PAK 4. U.S. Department of Veterans Affairs, University of Oklahoma Health Sciences Center, Oklahoma, USA

Corresponding author: Muhammad Taqi, dr.taqi227@yahoo.com

Abstract

Background
In this study, we compared the functional outcome of intra-articular injection of corticosteroid versus platelet-rich plasma (PRP) in patients with frozen shoulder (FS).

Methodology
This randomized controlled trial was conducted in the Department of Orthopedics, Mayo Hospital, Lahore, from January 2018 to December 2018. A total of 202 patients with FS aged 40 to 70 years were included. Patients with medical comorbidities such as chronic liver disease (assessed on history and serum bilirubin >2.0 mg/dl), chronic renal failure (assessed on history and serum creatinine >1.5 mg/dL), and chronic steroid use were excluded. Employing an anterior approach, subjects in groups A and B received one intra-articular injection of 2 mL PRP and 2 mL (80 mg) methylprednisolone acetate, respectively. Age, gender, duration of disease, and pre-injection and post-injection range of motion (ROM) (flexion, extension, abduction, external rotation, and internal rotation) were assessed. The University of California at Los Angeles Shoulder Score (UCLA) and visual analog scale (VAS) scores were measured and compared before and after the injection. All patients were followed at regular intervals post-therapy and the final functional outcome was measured after 12 weeks of therapy.

Results
Data were analyzed using SPSS version 20 (IBM Corp., Armonk, NY, USA). A p-value of 0.05 was considered significant when comparing flexion, abduction, external rotation, and internal rotation in both groups using the independent t-test. The ROM in group A (intra-articular PRP) improved significantly (p < 0.05) after injection compared to group B (intra-articular corticosteroid). The ROM after PRP for abduction was 147.09 ± 7.78, forward flexion 154.52 ± 6.48, external rotation 71.59 ± 7.43, and internal rotation 59.20 ± 3.96. The ROM in the steroid injection group for abduction was 129.07 ± 4.72, forward flexion 127.14 ± 7.87, external rotation 56.27 ± 5.93, and internal rotation 48.86 ± 4.90.

Conclusions
Intra-articular injection of PRP resulted in a substantial improvement in the VAS score, UCLA, and ROM when compared to intra-articular corticosteroid injection in patients with FS.

Introduction
Frozen shoulder (FS) is a common disease with high morbidity. Codman was the first to coin the phrase “frozen shoulder” in 1934 [1]. Because of adhesion and fibrosis in the glenohumeral (GH) capsule, which reduces joint space, FS affects the GH joint and restricts active and passive mobility. FS is estimated to have a 3-5% incidence rate and a 10-20% frequency among adults [2]. According to a previous study, there is no difference in pain and impairment between FS patients with and without diabetes [3]. Although this condition has a benign stage and recovers after two or three years, in certain circumstances, the symptoms and signs of the disease remain permanent. After three years, up to 40% of patients, to our knowledge, have persistent problems [4].

Several alternative therapies have been suggested such as benign neglect, oral corticosteroids, intra-
articular injections of corticosteroids, intra-articular injections of hyaluronic acid, physical therapy, deep heat regimens, manipulation under anesthesia, hydro-dilation, and arthroscopic release; however, the best treatment option remains debatable [5]. One of the most widely utilized treatments for FS is intra-articular corticosteroid injection [6,7].

As there is a paucity of literature available to compare functional outcomes of steroids with platelet-rich plasma (PRP), the goal of this study is to establish facts regarding the benefits and possible complications of intra-articular corticosteroid injections versus PRP injections. This study will help in evaluating and devising the better treatment option among the two approaches to ensure that these patients return to their routine life as soon as possible.

**Materials And Methods**

This randomized controlled trial was conducted in the Department of Orthopedic Surgery and Traumatology employing a probability simple random selection approach. Randomization was done using the lottery method and a transparent envelope was prepared; however, it was blinded by the chief researcher. Ethical approval was obtained from the university. The sample size was calculated to be 202 including 102 cases in group A and 100 cases in group B, with a 5% level of significance and 95% power. Patients between the ages of 40 and 70 years with a ≤6-month history of FS and loss of 100° ROM were included. Patients with a history of prior operations of the shoulder joint, medical comorbidities such as chronic liver disease (serum bilirubin >2.0 mg/dL), chronic renal failure (serum creatinine >1.5 mg/dL), chronic steroid use, old healed fractures, and drug allergies to steroids were excluded.

After obtaining approval from the institutional review board, informed written consent was obtained and the study goal was explained. Randomization was done using the lottery method, and patients were randomized into two groups A and B. All selected individuals were given the option of selecting a slip from mixed slips (half of the slips containing the letter "A" and the other half containing the letter "B") and were assigned to the selected group. Using the anterior approach, subjects in groups A and B received one intra-articular injection of 2 mL PRP and 2 mL (80 mg) methylprednisolone acetate, respectively, without ultrasound guidance. Throughout the procedure, aseptic conditions were maintained. Centrifugation was used to separate PRP from autologous blood. After the injection, the participants were sent home with instructions to limit shoulder joint movement for at least 48 hours and use paracetamol as a pain reliever. During each injection, adverse effects were reported. ROM was measured using a goniometer in anteroposterior and lateral planes. Patients were followed up in the outpatient department at four, eight, and twelve weeks post-injection. After two days, shoulder exercises were started. In both groups, the injection was administered by the researcher himself. All patients were followed at regular intervals post-therapy, and the final functional outcome using clinical examination was measured after 12 weeks of therapy. The improved ROM of ≥30° was considered clinically significant.

The means and standard deviations for age, illness duration, and pre- and post-injection ROM (flexion, abduction, external rotation, and internal rotation) were calculated. Gender and diabetes mellitus (yes/no) were used to determine frequency and percentages. In both groups, an independent t-test was performed to compare flexion, abduction, external rotation, and internal rotation, and a p-value of 0.05 was considered statistically significant. The University of California at Los Angeles Shoulder Score (UCLA) and visual analog scale (VAS) scores were measured and compared before and after the injection. Through stratification, effect modifiers such as age, gender, illness duration, and diabetes mellitus (yes/no) were controlled, and the post-stratification independent t-test was used. P-values of less than 0.05 were considered significant.

**Results**

In group A, 41.38% of the participants were males and 56.82% were females, and in group B, 40.91% of the participants were males and 59.09% were females. The male-to-female ratio was 1:1.4. The mean age of the patients in group A was 70.41 ± 4.67 years and in group B was 57.0 ± 7.74 years. The age range in this study was 40 to 70 years, with a mean age of 57.24 ± 7.71 years in both groups (Table 1). Of the 202 patients, the mean duration of disease was 5.15 ± 1.49 months (Table 2).
| Variables | Mean age SD (years) | Duration of disease | Gender |
|-----------|---------------------|---------------------|---------|
|           | 40–55 | 56–70 | Mean | <5 months | >5 months | Mean | Male | Female |
| Number of patients | Number of patients | Percentage of patients |
| Group A (102) | 47    | 55    | 52.41 ± 2.67 | 49 | 53 | 5.57 ± 1.49 | 41.38 | 56.82 |
| Group B (100) | 55    | 50    | 53.0 ± 3.74 | 68 | 32 | 4.86 ± 1.50 | 40.91 | 59.09 |

**TABLE 1: Demographic characteristics of the study participants.**
SD: standard deviation

| ROM             | Pre-injection ROM | Post-injection ROM | P-value |
|-----------------|-------------------|--------------------|---------|
|                 | Group A (102)     | Group B (100)      |         |
|                 | Mean | SD | Mean | SD | Mean | SD | Mean | SD |
| Forward flexion | 83.41 | 22.34 | 83.74 | 21.49 | 154.52 | 6.48 | 127.14 | 7.87 | 0.0001 |
| Abduction       | 65.13 | 17.61 | 64.98 | 17.18 | 147.09 | 7.78 | 129.07 | 4.72 | 0.0001 |
| External rotation | 38.33 | 12.19 | 38.02 | 11.79 | 71.59 | 7.43 | 56.27 | 5.93 | 0.0001 |
| Internal rotation | 28.33 | 22.19 | 28.02 | 21.79 | 59.20 | 3.96 | 48.86 | 4.90 | 0.0001 |

**TABLE 2: Comparison between pre-injection ROM and post-injection ROM.**
ROM: range of motion; SD: standard deviation

In group A, pre-injection mean ROM was forward flexion (83.41°), abduction (65.13°), external rotation (38.33°), and internal rotation (28.33°). In group B, pre-injection mean ROM was forward flexion (83.74°), abduction (64.98°), external rotation (38.02°), and internal rotation (28.02°). There was no significant difference between the two groups concerning the pre-injection ROM (forward flexion, abduction, external rotation, and internal rotation). As shown in Table 3, group A (intra-articular PRP) had a significant improvement (p = 0.05) in ROM compared to group B (intra-articular corticosteroid). In the study, the ROM after PRP (group A) for abduction was 147.09 ± 7.78, forward flexion 154.52 ± 6.48, external rotation 71.59 ± 7.43, internal rotation 59.20 ± 3.96. In the steroid injection group (group B), the ROM for abduction was 129.07 ± 4.72, forward flexion 127.14 ± 7.87, external rotation 56.27 ± 5.93, and internal rotation 48.86 ± 4.90. The acquired ROM in diabetics and non-diabetics is presented in Table 4. The pre-treatment VAS scores and UCLA were statistically similar in both groups. In all groups, there was a substantial improvement in pain and shoulder function after therapy (Table 5). The VAS score of group A after therapy was considerably lower than that of group B. The UCLA of group A was substantially higher than that of group B (p = 0.002 and p = 0.004, respectively) after therapy.
TABLE 3: Stratification according to the duration of disease.
ROM: range of motion; SD: standard deviation

| ROM             | Pre-injection <5 months | Post-injection >5 months |
|-----------------|-------------------------|--------------------------|
|                 | Group A (102)           | Group B (100)            | Group A (102) | Group B (100) |
| Forward flexion | Mean    | SD      | Mean    | SD      | Mean    | SD      | Mean    | SD      |
|                 | 54.24   | 6.80    | 67.20   | 7.58    | <0.001  |         | 154.78  | 6.31    | 127.0   | 8.75    | <0.001  |
| Abduction       | Mean    | SD      | Mean    | SD      |         |         |         |         |
|                 | 47.29   | 6.99    | 88.03   | 5.07    | <0.001  |         | 146.91  | 8.60    | 131.29  | 2.92    | <0.001  |
| External rotation | Mean    | SD      | Mean    | SD      |         |         |         |         |
|                 | 71.00   | 7.52    | 56.07   | 5.34    | <0.001  |         | 72.13   | 7.46    | 56.71   | 7.25    | <0.001  |
| Internal rotation | Mean    | SD      | Mean    | SD      |         |         |         |         |
|                 | 59.10   | 4.30    | 48.93   | 4.96    | <0.001  |         | 59.30   | 3.72    | 48.71   | 4.95    | <0.001  |

TABLE 4: Comparison of ROM between diabetic and non-diabetic patients.
ROM: range of motion; SD: standard deviation

| ROM             | Diabetic patients | Non-diabetic patients |
|-----------------|-------------------|-----------------------|
|                 | Group A (100)     | Group B (100)         | Group A (100) | Group B (100) |
| Forward flexion | Mean    | SD      | Mean    | SD      | Mean    | SD      | Mean    | SD      | Mean    | SD      | 0.0001  |
|                 | 53.77   | 7.51    | 67.00   | 7.41    | 0.0001  |         | 154.84  | 6.11    | 127.23  | 8.31    | 0.0001  |
| Abduction       | Mean    | SD      | Mean    | SD      |         |         |         |         |
|                 | 48.46   | 7.88    | 78.00   | 3.96    | 0.0001  |         | 146.52  | 7.80    | 129.81  | 5.12    | 0.0001  |
| External rotation | Mean    | SD      | Mean    | SD      |         |         |         |         |
|                 | 71.69   | 7.19    | 56.06   | 5.43    | 0.0001  |         | 71.55   | 7.64    | 56.42   | 6.36    | 0.0001  |
| Internal rotation | Mean    | SD      | Mean    | SD      |         |         |         |         |
|                 | 60.15   | 3.60    | 50.00   | 5.02    | 0.0001  |         | 58.81   | 4.09    | 64.08   | 4.76    | 0.0001  |

TABLE 5: Comparison of shoulder pain and functions.
VAS: visual analog scale; UCLA: University of California at Los Angeles Shoulder Score

| Score   | Pre-injection | Post-injection |
|---------|---------------|----------------|
|         | Group A       | Group B        | Group A | Group B | P-value | Group A | Group B | P-value |
| VAS     | 8.9 ± 1.01    | 9.5 ± 0.6      | 0.06    | 0.85 ± 0.52 | 2.3 ± 1.6 | 0.004  |
| UCLA    | 11.6 ± 1.64   | 11.9 ± 2.04    | 0.93    | 27 ± 1.9   | 23 ± 6.62 | 0.002  |

Discussion
PRP is a small volume of plasma containing an autogenous concentration of human platelets. PRP has the ability to generate collagen and growth factors, as well as potentially boost stem cells, enhancing the healing process by providing large concentrations of alpha-granules carrying physiologically active subunits (such as vascular endothelial growth factor and transforming growth factor-β) to the areas of soft tissue damage [8,9]. Adhesive capsulitis is more frequent in the fifth and sixth decades of life, and people under the age of 40 should be evaluated for other medical conditions. There is no evidence of racial prejudice in the literature [10,11]. In our study, 37 (36.54%) males and 51 (63.46%) females made up a male-to-female ratio of 1:1.4. These findings corroborate the findings of several earlier studies, which reported that the incidence of FS is two times higher in females than in males [12,13]. Diabetes mellitus has been identified as one of the risk factors for FS in several previous studies, and its incidence has been reported to be significant in diabetic individuals [2].
When comparing group A (intra-articular PRP) to group B (control), the results showed that group A had a significant improvement (p = 0.05) in the ROM after injection (intra-articular injection of corticosteroid). In this study, the ROM after PRP was abduction 147.09 ± 7.78, forward flexion 154.52 ± 6.48, external rotation 71.59 ± 7.45, and internal rotation 59.20 ± 5.96 in comparison to abduction 129.07 ± 4.72, forward flexion 127.14 ± 7.87, external rotation 56.27 ± 5.93, and internal rotation 48.86 ± 4.90 in the steroid injection group. A study about the functional outcome of FS by Kothari et al. [11] showed that the active ROM after PRP was abduction 142.3 ± 22.9, forward flexion 145.5 ± 13.5, external rotation 80.2 ± 15.8, and internal rotation 57.5 ± 10.7 compared to abduction 129.7 ± 21.8, forward flexion 135.1 ± 18.5, external rotation 71.4 ± 18.3, and internal rotation 50.2 ± 13.4 in the steroid injection group [14]. The result of this study cannot be generalized because of its small sample size.

Rawat et al. investigated 32 patients with FS who received intra-articular steroid injections. After 12 weeks of follow-up, pain alleviation was statistically significant [15]. According to Shah and Lewis, multiple corticosteroid injections were helpful until 16 weeks among FS patients [16]. The required duration of treatment is greater compared to PRP injections. Aslani et al. [2] found that two consecutive treatments of PRP with a four-week gap increased the functional ROM and alleviated pain in a volunteer with FS. With PRP therapy, he saw a two-fold improvement in ROMs [17].

PRP and procaine were found to be helpful in treating FS in the study by Lin. The PRP treatment was more effective and lasted longer than the procaine treatment. The UCLA improved linearly in the PRP group but reduced to a lower level at the last three-month follow-up visit in the procaine group. Following one week, one month, and three months after the initial injection, VAS scores in both the PRP and control groups decreased [18,19].

This study had several limitations. Patients in various stages of FS were included in the study without stratification. The use of ultrasound for intra-articular injection was not evaluated. Moreover, the sample size was small. Multicenter controlled trials are required for more accurate results.

Conclusions

In comparison to intra-articular corticosteroid injection, there is a substantial improvement in VAS score, UCLA, and ROM in patients with FS following intra-articular injection of PRP. Hence, we believe that intra-articular injections of PRP should be utilized frequently in the treatment of FS to achieve better outcomes.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. College of Physicians and Surgeons Pakistan issued approval CPSP/REU/OSG-2016-066-1713. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Uppal HS, Evans JP, Smith C: Frozen shoulder: a systematic review of therapeutic options . World J Orthop. 2015, 6:267-8. 10.5312/wjo.v6.i2.263
2. Aslani H, Nourbaksh ST, Zafarani Z, Ahmadi-Bani M, Anandoo ME, Beigy M, Salehi S: Platelet-rich plasma for frozen shoulder: a case report. Arch Bone & Jt Surg. 2016, 4:90-3.
3. Uddin MM, Khan AA, Haig AI, Uddin MK: Presentation of frozen shoulder among diabetic and non-diabetic patients. J Clin Orthop Trauma. 2014, 5:195-8. 10.1016/j.jcot.2014.09.008
4. Lewis J: Frozen shoulder contracture syndrome - etiology, diagnosis and management . Man Ther. 2015, 20:2-9. 10.1016/j.math.2014.07.006
5. Lim TK, Koh KH, Shon MS, Lee SW, Park YE, Yoo IC: Intra-articular injection of hyaluronate versus corticosteroid in adhesive capitisitis. Orthopedics. 2014, 37:e860-5. 10.3928/01477447-20140924-51
6. Ranalletta M, Rossn LA, Bongiovanni SL, Tanoira I, Elizondo CM, Maignon GD: Corticosteroid injections accelerate pain relief and recovery of function compared with oral NSAIDs in patients with adhesive capsulitis: a randomized controlled trial. Am J Sports Med. 2016, 44:474-81. 10.1177/0363546515616238
7. Tasto JP, Elias DW: Adhesive capsulitis. Sports Med Arthrosc Rev. 2007, 15:216-21. 10.1097/01.sma.0000282633.98827.4c
8. Balci N, Balci MK, Tüzünzer S:Shoulder adhesive capsulitis and shoulder range of motion in type II diabetes mellitus: association with diabetic complications. J Diabetes Complications. 1999, 13:155-40. 10.1016/s1056-8727(99)00037-9
9. Kordella T: Frozen shoulder & diabetes. Frozen shoulder affects 20 percent of people with diabetes. Proper treatment can help you work through it. Diabetes Forecast. 2002, 55:60-6.
10. Ogilvie-Harris DJ, Biggs DJ, Fitisailos DP, MacKay M: The resistant frozen shoulder. Manipulation versus
arthroscopic release. Clin Orthop Relat Res. 1995, 238-48.

11. Kothari SY, Srikanth V, Singh N: Comparative efficacy of platelet rich plasma injection, corticosteroid injection and ultrasonic therapy in the treatment of periarthritis shoulder. J Clin Diagn Res. 2017, 11:RC15-8. 10.7860/JCDR/2017/17060.9895

12. Mishra A, Woodall J Jr, Vieira A: Treatment of tendon and muscle using platelet-rich plasma. Clin Sports Med. 2009, 28:115-25. 10.1016/j.csm.2008.08.007

13. Marx RE: Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001, 10:225-8. 10.1097/00008505-200110000-00002

14. Kumar R, Bansal N, Sidhu AS, Kular PS, Sharma S, Jain G, Shivam: An observational study to compare the outcome of local steroid injections and ultrasonic wave therapy in frozen shoulder patients. Int J Orthop Sci. 2018, 4:98-101.

15. Rawat MS, Juyal A, Agarwal A: Evaluation of the role of intra-articular steroid injection in frozen shoulder. Int J Orthop Sci. 2018, 4:792-4.

16. Shah N, Lewis M: Shoulder adhesive capsulitis: systematic review of randomised trials using multiple corticosteroid injections. Br J Gen Pract. 2007, 57:662-7.

17. Kesikburun S, Tan AK, Yilmaz B, Yasar E, Yazicioglu K: Platelet-rich plasma injections in the treatment of chronic rotator cuff tendinopathy: a randomized controlled trial with 1-year follow-up. Am J Sports Med. 2013, 41:2609-16. 10.1177/0363546513496542

18. Gautam VK, Verma S, Batra S, Bhatnagar N, Arora S: Platelet-rich plasma versus corticosteroid injection for recalcitrant lateral epicondylitis: clinical and ultrasonographic evaluation. J Orthop Surg (Hong Kong). 2015, 23:1-5. 10.1177/230949901502300101

19. Lin J: Platelet-rich plasma injection in the treatment of frozen shoulder: a randomized controlled trial with 6-month follow-up. Int J Clin Pharmacol Ther. 2018, 56:566-71. 10.5414/CF203262